Passage Bio, Inc.

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Passage Bio’s primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.

Current securities

1. S-4/A filingSep 21, 2026
2. S-4/A filingSep 3, 2026
3. 425 filingSep 3, 2026
4. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesSep 3, 2026
5. 10-Q filingAug 10, 2026